An integrase inhibitor called dolutegravir, recently approved for the treatment of individuals infected with HIV, has been reformulated into a long-acting version that appears to protect monkeys from subsequent infections, reports a team led by researchers at Rockefeller University, in New York City (Andrews CD et al. Science. 2014;343:1151-1154). The drug is also being tested as a prophylactic agent in people who do not have HIV but are at high risk for infection. The analog of dolutegravir is meant to be injected monthly or quarterly rather than daily.
Hampton T. Long-Acting HIV Drug May Be Effective as a Prophylactic Agent. JAMA. 2014;311(17):1722. doi:10.1001/jama.2014.4521